Probabilistic Methylation Modeling for Lung Cancer Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively detect and characterize the heterogeneous histologies and subtypes of lung cancers, particularly in cases of small cell lung cancer transformation, leading to resistance to treatments like EGFR-TKIs, chemotherapy, and immunotherapy, necessitating a comprehensive multi-modal detection platform for methylation analysis.
Innovation Solution
A probabilistic generative modeling method is employed to analyze methylation data, incorporating parameters and probabilistic distributions to determine quantitative metrics for characterizing tumor subtypes, enabling accurate detection and treatment recommendations for lung adenocarcinomas, squamous cell carcinomas, small cell lung cancer, and non-small cell lung cancer, using methylation profiles and therapeutic agents like cisplatin, carboplatin, and EGFR inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional single-modality detection methods are used, then the analysis process is simple, but the ability to detect and characterize heterogeneous histologies and subtypes is insufficient
Solution Approach 1:
The patent combines multiple detection modalities (genomic sequencing, methylation analysis, and histological examination) into a unified multi-modal detection platform. This integration allows simultaneous assessment of different cancer characteristics from the same sample, improving detection accuracy for heterogeneous histologies and subtypes while managing system complexity through coordinated analysis workflows.
Solution Approach 2:
The detection platform is designed with multi-functional capabilities that can identify various cancer subtypes (adenocarcinoma, squamous cell carcinoma, small cell lung cancer) and characterize their specific features through different analytical methods. The system universally handles diverse sample types and provides comprehensive characterization across multiple biological dimensions.
2Loss of information
If comprehensive multi-modal detection is implemented, then the characterization of tumor subtypes improves, but the analysis time and processing complexity increase
Solution Approach 1:
The comprehensive analysis is divided into distinct modular components: genomic sequencing for mutation detection, methylation analysis for epigenetic characterization, and histological examination for morphological assessment. Each module processes specific aspects of tumor biology independently, allowing parallel execution and reducing overall analysis time while maintaining complete characterization through integration of results.
Solution Approach 2:
The system performs preliminary data processing and feature extraction during the detection phase, preparing standardized outputs that facilitate rapid integration and interpretation. Pre-processing steps include normalization, quality control, and initial classification, which reduce the time required for final analysis and decision-making.
3Reliability
If detailed methylation analysis is performed, then the detection of treatment resistance mechanisms improves, but the complexity of data processing increases
Solution Approach 1:
The patent introduces computational intermediaries and standardized algorithms that bridge the raw methylation data and treatment resistance detection. These intermediaries include pre-trained machine learning models and decision support tools that automatically interpret methylation patterns, identify resistance mechanisms, and generate actionable insights, reducing the complexity burden on users while maintaining high detection reliability.
Data Source
AI summary
Disclosed herein are methods, compositions, and devices for use in diagnosis and treatment of cancer. The methods include a generative probabilistic accounting for the characteristics of methylation data, which includes random silencing and in possesses sparsity as a result. Here, the technique finds application in subtyping, determining disease transition and formation, among other oncology applications.